Zura Bio presents trial poster. Guggenheim targets Zura Bio stock at USD 20

Published on 10/18/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TibuSHIELD targets hidradenitis suppurativa in Phase 2 on October 15, 2026. Zura Bio stock has a USD 20 target and reports November 18, 2026.

Trial data and analyst targets

Zura Bio presented a TibuSHIELD trial poster on October 15, 2026.
Guggenheim maintained a USD 20.00 price target on October 2, 2026.
Zura Bio stock closed at USD 3.88 on Nasdaq on October 16, 2026.
Zura Bio is scheduled to report third-quarter 2026 results on November 18, 2026.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio (ISIN KYG9TY5A1016) presented a TibuSHIELD trial poster on October 15, 2026, putting its Phase 2 program for hidradenitis suppurativa at the center of the latest company update. Zura Bio said the study evaluates tibulizumab, an investigational bispecific antibody designed to target IL-17 and BAFF.

Phase 2 program advances

The poster described the design of TibuSHIELD, while the company is also developing tibulizumab in systemic sclerosis. Zura Bio's investor-relations page identifies TibuSHIELD and TibuSURE as separate Phase 2 studies and says a third study for polymyalgia rheumatica is planned by year-end 2026.

Three dated milestones

On August 11, 2026, Zura Bio reported a second-quarter GAAP net loss of USD 26.30 million; Markets Insider compared that with a USD 15.99 million loss in the year-earlier quarter. On October 2, 2026, Markets Insider reported that Guggenheim reiterated a Buy rating and a USD 20.00 target. On October 15, 2026, Zura Bio published the TibuSHIELD poster update.

What does the USD 20 target mean?

Guggenheim's USD 20.00 target is 415.46 percent above Zura Bio's USD 3.88 Nasdaq closing price from October 16, 2026. That gap reflects the binary nature of clinical development, with the upcoming TibuSHIELD readout carrying more weight than current revenue because Zura Bio remains a clinical-stage company.

Next date for investors

The next explicitly dated corporate event is Zura Bio's third-quarter 2026 earnings report on November 18, 2026, according to Barrons. The same page lists an average analyst target of USD 18.83 from eight ratings, while the second-quarter figures show net income of minus USD 26.39 million and cash of USD 205.13 million as of June 30, 2026.

Nasdaq price and valuation

Zura Bio was last at USD 3.88 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, with a market capitalization of USD 371.8 million and a 52-week range of USD 3.15 to USD 7.44. The clinical timetable and the distance between the share price and analyst targets leave trial results as the central valuation variable.

The further course of trading is shown by the continuously updated real-time quote of Zura Bio stock.